GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia

NCT ID: NCT01518517

Last Updated: 2022-02-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 85 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-12-31
• Study Completion Date: 2016-10-31

Brief Summary

Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also neutralize asparaginase without any clinical signs of hypersensitivity (silent inactivation). GRASPA improves pharmacokinetics, tolerability and maintain circulating asparaginase activity due to the protective barrier of the erythrocyte membrane.

This study is run to confirm the benefit/risk profile of GRASPA at 150 IU/kg in combination with the COOPRALL regimen in adults and children patients with relapsed ALL, with or without known hypersensitivity to L-asparaginase.

Detailed Description

This open, randomized international Phase 2/3 study will enrol patients with relapsed ALL. The co-primary endpoints were the duration of asparagine depletion < 2µmol/L and the incidence of asparaginase hypersensitivity during induction. Key secondary endpoints are complete remission (CR), minimal residual disease (MRD), event free survival (EFS) and overall survival (OS).The study was powered to detect 3-fold difference in the incidence of allergic reactions between treatments. patients will be randomized to GRASPA or to Reference L-asparaginase. Patients with history of hypersensitivity to previous L-asparaginase treatment will be treated with GRASPA (exploratory arm)

Conditions

Acute Lymphoblastic Leukemia, in Relapse

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GRASPA

Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).

GRASPA® administration takes place as below:

• for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)
• for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)

Group Type: EXPERIMENTAL

GRASPA

Intervention Type: DRUG

one injection of GRASPA 150 IU/kg at each cycle of chemotherapy

reference L-asparaginase

For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).

•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).

NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)

•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles).

Group Type: ACTIVE_COMPARATOR

L-asparaginase

Intervention Type: DRUG

3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy

Interventions

GRASPA

one injection of GRASPA 150 IU/kg at each cycle of chemotherapy

Intervention Type: DRUG

L-asparaginase

3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy

Intervention Type: DRUG

Other Intervention Names

ERY001; KIDROLASE

Eligibility Criteria

Inclusion Criteria

• Patient from 1 to 55 years old (Children and adolescents from 1 to 17 years/ Adults from 18 to 55 years)
• Patients with 1st ALL relapse, which could be either isolated bone marrow relapse, or combined (medullary and extra-medullary) relapse, or extra-medullary isolated relapse; or lymphoblastic lymphoma (excepted Burkitt lymphoma) OR Failure to ALL first line treatment (no complete remission obtained)
• Patient previously treated with free E.Coli L-asparaginase form or pegylated one
• Performance Status ≤ 2 (WHO score)
• Patient informed and consent provided (the 2 parents need to consent when children are below 18)

Exclusion Criteria

• ALL t(9;22) and/or BCR-ABL positive (Philadelphia chromosome positive)
• Patient with 2nd relapse and over
• Women of childbearing potential without effective contraception as well as pregnant or breast feeding women
• Patient unable to receive treatments used in global chemotherapy protocols, due to general or visceral conditions such as:Severe cardiac impairment (NYHA grade 3 or 4 cardiomyopathy)/Serum creatinine 2 x ULN unless related to ALL /ALT or AST 5 x ULN unless related to ALL /Pancreatitis history /Other malignancy that ALL / Severe Infection, HIV positive, active hepatitis related to B or C virus infection / Trisomy 21 / Other serious conditions according to investigator's opinion
• Known grade 4 allergic reaction to E.Coli L-asparaginase (according NCI-CTCAE, Version 3.0)
• History of grade 3 transfusional incident
• Presence of specific anti-erythrocyte antibodies preventing from getting a compatible erythrocyte concentrate for the patient
• Patient under concomitant treatment likely to cause hemolysis
• Patient undergoing yellow fever vaccination
• Patient under phenytoin treatment
• Patient included in previous clinical study less than 6 weeks ago

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ERYtech Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yves Bertand, MD

Role: PRINCIPAL_INVESTIGATOR

Locations

Hopital Des Enfants Reine Fabiola

Brussels, , Belgium

Chr de La Citadelle

Liège, , Belgium

Chu D'Angers

Angers, , France

Hopital Saint Jacques

Besançon, , France

Hopital Pellegrin Enfants

Bordeaux, , France

Chu Estaing

Clermont-Ferrand, , France

Hopital Henri Mondor

Créteil, , France

Chu Grenoble

Grenoble, , France

Chru Lille - Hop Jeanne de Flandres

Lille, , France

Institut Hematologie Oncologie Pediatrique

Lyon, , France

Institut Paoli Calmettes

Marseille, , France

Hopital Mere Enfant

Nantes, , France

Hotel Dieu

Nantes, , France

Hopital de L'Archet 2

Nice, , France

Hopital Armand Trousseau

Paris, , France

Hopital Robert Debre

Paris, , France

Hopital Saint Louis

Paris, , France

Hopital Haut-Leveque

Pessac, , France

Hopital Lyon Sud

Pierre-Bénite, , France

Chru Hopital Sud

Rennes, , France

Centre Henri Becquerel

Rouen, , France

Chu Hopital Nord

Saint-Etienne, , France

Institut Cancerologie de La Loire

Saint-Priest-en-Jarez, , France

Hopital de Hautepierre

Strasbourg, , France

Chu de Toulouse Enfants

Toulouse, , France

Hotel Dieu

Valenciennes, , France

Hopital Brabois Enfants

Vandœuvre-lès-Nancy, , France

Hopital de Brabois

Vandœuvre-lès-Nancy, , France

Countries

Belgium; France

Other Identifiers

GRASPALL2009-06

Identifier Type: -

Identifier Source: org_study_id